In Brief: Vysis v. Oncor
This article was originally published in The Gray Sheet
Oncor will not contest during an April hearing in the U.S. District Court of San Francisco that its sequence fluorescence in situ hybridization probes for analysis of chromosome preparations (in metaphase) infringe a University of California patent (No. 5,447,841), rights to which are licensed exclusively by Vysis. Instead, Oncor maintains that the patent is "invalid and unenforceable" and the court will not rule in Vysis' favor. In addition, Oncor "does not concede infringement of Oncor's Inform HER-2/neu gene detection system," which involves analysis of nuclei of whole cells. Vysis, which employs the technology in its fluorescence in situ hybridization (FISH) probes, maintains that Oncor concedes in a recent letter to the court that its products contain repetitive sequences of DNA, "a concession that will make it far easier for Vysis to prove use of the products infringes the patent"...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.